• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Mersana Therapeutics Inc.

    11/15/24 4:45:57 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRSN alert in real time by email
    SC 13D/A 1 d863651dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    SCHEDULE 13D

    (Rule 13d-101)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(a) and Amendments Thereto Filed

    Pursuant to § 240.13d-2(a)

    Under the Securities Exchange Act of 1934

    (Amendment No. 6)

     

     

    MERSANA THERAPEUTICS, INC.

    (Name of Issuer)

    Common Stock, $0.0001

    par value per share

    (Title of Class of Securities)

    59045L106

    (CUSIP Number)

    Bain Capital Life Sciences Investors, LLC

    200 Clarendon Street

    Boston, MA 02116

    617-516-2000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    November 13, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 59045L106    13D    Page 2 of 6

     

     1   

     Names of reporting persons

     

     Bain Capital Life Sciences Fund II, L.P.

     2  

     Check the appropriate box if a member of a group

     (a) ☐  (b) ☐

     

     3  

     SEC use only

     

     4  

     Source of funds

     

     WC

     5  

     Check if disclosure of legal proceedings is required pursuant to Item 2(d) or 2(e)

     

     ☐

     6  

     Citizenship or place of organization

     

     Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

     

        7   

     Sole voting power

     

     0 shares of Common Stock

        8  

     Shared voting power

     

     3,294,423 shares of Common Stock

        9  

     Sole dispositive power

     

     0 shares of Common Stock

       10  

     Shared dispositive power

     

     3,294,423 shares of Common Stock

    11   

     Aggregate amount beneficially owned by each reporting person

     

     3,294,423 shares of Common Stock

    12  

     Check if the aggregate amount in Row (11) excludes certain shares

     

     ☐

    13  

     Percent of class represented by amount in Row (11)

     

     2.7%

    14  

     Type of reporting person

     

     PN


    CUSIP No. 59045L106    13D    Page 3 of 6

     

     1   

     Names of reporting persons

     

     BCIP Life Sciences Associates, LP

     2  

     Check the appropriate box if a member of a group

     (a) ☐  (b) ☐

     

     3  

     SEC use only

     

     4  

     Source of funds

     

     WC

     5  

     Check if disclosure of legal proceedings is required pursuant to Item 2(d) or 2(e)

     

     ☐

     6  

     Citizenship or place of organization

     

     Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

     

        7   

     Sole voting power

     

     0 shares of Common Stock

        8  

     Shared voting power

     

     401,244 shares of Common Stock

        9  

     Sole dispositive power

     

     0 shares of Common Stock

       10  

     Shared dispositive power

     

     401,244 shares of Common Stock

    11   

     Aggregate amount beneficially owned by each reporting person

     

     401,244 shares of Common Stock

    12  

     Check if the aggregate amount in Row (11) excludes certain shares

     

     ☐

    13  

     Percent of class represented by amount in Row (11)

     

     0.3%

    14  

     Type of reporting person

     

     PN


    CUSIP No. 59045L106    13D    Page 4 of 6

     

     1   

     Names of reporting persons

     

     BCLS II Investco, LP

     2  

     Check the appropriate box if a member of a group

     (a) ☐  (b) ☐

     

     3  

     SEC use only

     

     4  

     Source of funds

     

     WC

     5  

     Check if disclosure of legal proceedings is required pursuant to Item 2(d) or 2(e)

     

     ☐

     6  

     Citizenship or place of organization

     

     Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

     

        7   

     Sole voting power

     

     0 shares of Common Stock

        8  

     Shared voting power

     

     4,968,006 shares of Common Stock

        9  

     Sole dispositive power

     

     0 shares of Common Stock

       10  

     Shared dispositive power

     

     4,968,006 shares of Common Stock

    11   

     Aggregate amount beneficially owned by each reporting person

     

     4,968,006 shares of Common Stock

    12  

     Check if the aggregate amount in Row (11) excludes certain shares

     

     ☐

    13  

     Percent of class represented by amount in Row (11)

     

     4.0%

    14  

     Type of reporting person

     

     PN


    CUSIP No. 59045L106    13D    Page 5 of 6

     

    This Amendment No. 6 to Schedule 13D relates to the Common Stock of Mersana Therapeutics, Inc. (the “Issuer”) and amends the initial statement on Schedule 13D filed by the Reporting Persons on April 17, 2020, as amended by Amendment No. 1 filed on January 12, 2021, Amendment No. 2 filed on January 3, 2022, Amendment No. 3 filed on February 8, 2022, Amendment No. 4 filed on April 14, 2022 and Amendment No. 5 filed on May 11, 2022 (the “Initial Statement” and, as further amended by this Amendment No. 6, the “Schedule 13D”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Initial Statement.

    On November 13, 2024, the Issuer filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 with the Securities and Exchange Commission, which disclosed that the Issuer’s total number of outstanding shares of Common Stock had increased to 123,532,909. This Amendment No. 6 is being filed to report a decrease in the percentage of outstanding shares of Common Stock that the Reporting Persons may be deemed to beneficially own.

    Item 5. Interest in Securities of the Issuer

    Item 5 of the Initial Statement is hereby amended and restated as follows:

    The information set forth in Items 2 and 3 and on the cover pages of this Schedule 13D is incorporated by reference in its entirety into this Item 5.

    (a) – (b) As of the date hereof, BCLS II holds 3,294,423 shares of Common Stock, representing approximately 2.7% of the outstanding shares of Common Stock, BCIPLS holds 401,244 shares of Common Stock, representing approximately 0.3% of the outstanding shares of Common Stock, and BCLS II Investco holds 4,968,006 shares of Common Stock, representing approximately 4.0% of the outstanding shares of Common Stock. As a result of the foregoing and the relationships described in Item 2(a) of this Schedule 13D, the Reporting Persons may be deemed to beneficially own in the aggregate 8,663,673 shares of Common Stock, representing approximately 7.0% of the outstanding shares of Common Stock. The percentage of the outstanding shares of Common Stock held by the Reporting Persons is based on 123,532,909 shares of Common Stock outstanding as of November 8, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.

    (c) Not applicable.

    (d) Except as otherwise described in this Item 5, no one other than the Reporting Persons has the right to receive, or the power to direct the receipt of, dividends from, or the proceeds form the sale of, any of the Common Stock beneficially owned by the Reporting Persons as described in this Item 5.

    (e) Not applicable.


    CUSIP No. 59045L106    13D    Page 6 of 6

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: November 15, 2024     Bain Capital Life Sciences Fund II, L.P.
        By: Bain Capital Life Sciences Investors II, LLC, its general partner
        By: Bain Capital Life Sciences Investors, LLC, its manager
        By:  

    /s/ Andrew Hack

        Name: Andrew Hack
        Title: Partner
        BCIP Life Sciences Associates, LP
        By: Boylston Coinvestors, LLC, its general partner
        By:  

    /s/ Andrew Hack

        Name: Andrew Hack
        Title: Authorized Signatory
        BCLS II Investco, LP
        By: BCLS II Investco (GP), LLC, its general partner
        By: Bain Capital Life Sciences Fund II, L.P., its managing member
        By: Bain Capital Life Sciences Investors II, LLC, its general partner
        By: Bain Capital Life Sciences Investors, LLC, its manager
        By:  

    /s/ Andrew Hack

        Name: Andrew Hack
        Title: Partner
    Get the next $MRSN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRSN

    DatePrice TargetRatingAnalyst
    2/6/2025Outperform
    William Blair
    11/15/2024$5.00Buy
    Citigroup
    3/19/2024$5.00Underweight → Neutral
    JP Morgan
    2/29/2024$6.00Neutral → Buy
    BTIG Research
    2/29/2024$7.00Neutral → Buy
    Guggenheim
    2/29/2024$2.00 → $7.00Neutral → Outperform
    Wedbush
    12/4/2023$1.00 → $5.00Neutral → Buy
    Citigroup
    7/28/2023$7.00 → $1.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $MRSN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Alleva Lawrence M

    4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

    6/13/25 5:15:12 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hack Andrew A. F.

    4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

    6/13/25 5:10:40 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Dere Willard H

    4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

    6/13/25 5:02:42 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRSN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Mersana Therapeutics

    William Blair initiated coverage of Mersana Therapeutics with a rating of Outperform

    2/6/25 7:08:59 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup resumed coverage on Mersana Therapeutics with a new price target

    Citigroup resumed coverage of Mersana Therapeutics with a rating of Buy and set a new price target of $5.00

    11/15/24 8:15:56 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics upgraded by JP Morgan with a new price target

    JP Morgan upgraded Mersana Therapeutics from Underweight to Neutral and set a new price target of $5.00

    3/19/24 7:51:31 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRSN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results

    More than 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts in post-topoisomerase-1 inhibitor ADC (post-topo-1) triple-negative breast cancer (TNBC)Plan to report initial clinical data from Emi-Le expansion cohorts in second half of 2025Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter ended June 30, 2025. "During the second quarter, we were excited to

    8/13/25 7:00:00 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025

    CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2025 on Wednesday, August 13, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersana

    8/6/25 8:00:18 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics Announces 1-for-25 Reverse Stock Split

    CAMBRIDGE, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will implement a 1-for-25 reverse stock split of the issued shares of the company's common stock (the Reverse Stock Split), effective at 5:00 p.m. Eastern Time on July 25, 2025. The Reverse Stock Split was approved by the company's stockholders at the company's Annual Meeting of Stockholders held on June 12, 2025, with the final ratio subsequently determined by the company's Board of Directors. One of the primary go

    7/24/25 8:31:52 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRSN
    SEC Filings

    View All

    SEC Form 10-Q filed by Mersana Therapeutics Inc.

    10-Q - Mersana Therapeutics, Inc. (0001442836) (Filer)

    8/13/25 8:56:20 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Mersana Therapeutics, Inc. (0001442836) (Filer)

    8/13/25 7:13:33 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Mersana Therapeutics, Inc. (0001442836) (Filer)

    7/24/25 8:40:38 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRSN
    Leadership Updates

    Live Leadership Updates

    View All

    Mersana Therapeutics Announces Changes in Leadership

    Anna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of DirectorsMartin Huber, M.D., current member of the Board of Directors, to be named President and CEOBrian DeSchuytner named Chief Operating Officer; Mohan Bala, Ph.D., named Chief Development Officer CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the retirement of Anna Protopapas, President and CEO, effective September 10, 2023, and the

    9/6/23 7:00:40 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics Provides Statement About SVB

    CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided an update about its capital resources. A de minimis amount of Mersana's capital is currently held in a checking account at Silicon Valley Bank (SVB). The balance of the company's capital resources is held in a custodial account managed by another institution and in money market funds of institutions other than SVB. Mersana has a loan and security agreement with Oxford Finance LLC and SVB. As previously

    3/10/23 7:10:38 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics Announces Appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership

    CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership, effective Monday, October 25, 2021. Dr. Bala will assume strategic product planning responsibilities from Brian DeSchuytner who has been named SVP and Chief Financial Officer. Mr. DeSchuytner will continue to lead finance, business development, corporate strategy and investor relations and remain Mersana's pri

    10/25/21 8:00:00 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRSN
    Financials

    Live finance-specific insights

    View All

    Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results

    More than 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts in post-topoisomerase-1 inhibitor ADC (post-topo-1) triple-negative breast cancer (TNBC)Plan to report initial clinical data from Emi-Le expansion cohorts in second half of 2025Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter ended June 30, 2025. "During the second quarter, we were excited to

    8/13/25 7:00:00 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025

    CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2025 on Wednesday, August 13, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersana

    8/6/25 8:00:18 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

    In a release issued under the same headline earlier today by Mersana Therapeutics, Inc. (NASDAQ:MRSN), please note that there was a transcription error in the last cell of the first table. The Median OS should have been 5.7 months rather than 1.7 months. The corrected release follows: Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results Updated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025 ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving intermediate dosesEncouraging preliminary time-to-event data in triple-negative breast cancer (

    5/15/25 9:20:09 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRSN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Mersana Therapeutics Inc.

    SC 13D/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

    11/15/24 4:45:57 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mersana Therapeutics Inc.

    SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

    11/14/24 5:45:55 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mersana Therapeutics Inc.

    SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

    11/14/24 6:01:51 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care